The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500113481

Enrollment

Unknown

Registered

2025-11-28

Start date

2025-11-28

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Paroxetine group:Take paroxetine orally

Paroxetine combined with liraglutide group:After subcutaneous injection of liraglutide, oral administration of paroxetine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Inpatients; 2. Age: 18 to 65 years old (inclusive), gender not limited. 3. Meet the DSM-5 diagnostic criteria for depression; 4. Screening and baseline Hamilton Depression Scale: HAMD-24 score >=20 points; 5. No history of electroconvulsive therapy; 6. No psychotropic drugs have been taken within two weeks prior to enrollment; 7. No drugs that have an impact on intestinal microbiota have been taken within one week before enrollment; 8.BMI>=27kg/m ^2; 9. The patient himself/herself or his/her legal guardian signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Has a history of schizophrenia, alcohol and drug dependence; 2. Have serious suicidal behaviors or ideas; 3. Have organic brain diseases; 4. Those with severe abnormalities in heart, liver or kidney functions; 5. Pregnant and lactating women; 6. Patients with metabolic syndrome (diabetes, pathological obesity, etc.); 7. Taking drugs that have an impact on intestinal microbiota in the past three months; 8. Currently participating in other drug clinical research or using GLP-1-related preparations; 9. Allergic to the test drug; 10. Those whose thyroid color Doppler ultrasound showed TI-RADS class 3 or above before enrollment; 11. Patients with a history of medullary thyroid carcinoma or a family history, as well as those with multiple endocrine tumor syndrome.

Design outcomes

Primary

Measure	Time frame
HAMD-24 scale score;	—

Secondary

Measure	Time frame
HAMA Anxiety Scale score;Body weight;Score of the Antidepressant Side Effects Rating Scale;	—

Countries

China

Contacts

Public ContactHonghong Yao;Yonggui Yuan

Zhongda Hospital Affiliated to Southeast University;School of Medicine, Southeast University

yao2h@163.com+86 25 8327 2551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026